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http://dx.doi.org/10.1016/j.ccell.2015.04.011SUMMARYHow loss-of-function of GATA3 contributes to the development of breast cancer is poorly understood. Here,
we report that GATA3 nucleates a transcription repression program composed of G9A and MTA3-, but not
MTA1- or MTA2-, constituted NuRD complex. Genome-wide analysis of the GATA3/G9A/NuRD(MTA3)
targets identified a cohort of genes including ZEB2 that are critically involved in epithelial-to-mesenchymal
transition and cell invasion. We demonstrate that the GATA3/G9A/NuRD(MTA3) complex inhibits the invasive
potential of breast cancer cells in vitro and suppresses breast cancer metastasis in vivo. Strikingly, the
expression of GATA3, G9A, and MTA3 is concurrently downregulated during breast cancer progression,
leading to an elevated expression of ZEB2, which, in turn, represses the expression of G9A andMTA3 through
the recruitment of G9A/NuRD(MTA1).INTRODUCTION
GATA3 is the most highly expressed transcription factor in the
mammary epithelium and is expressed exclusively in the luminal
epithelial cell population where it not only specifies, but also
maintains luminal epithelial cell differentiation (Asselin-Labat
et al., 2007; Kouros-Mehr et al., 2006). However, the expression
of GATA3 is progressively lost during luminal breast cancer pro-
gression, and low GATA3 expression is strongly correlated with
higher histologic grade, poor differentiation, positive lymph
nodes, estrogen receptor negative and progesterone receptor
negative status, and HER2/neu overexpression, all indicators
of poor prognosis (Kouros-Mehr et al., 2008; Yoon et al.,
2010). In addition, mutations in GATA3 that diminish or abolish
its DNA-binding ability are commonly found in human breastSignificance
Our study suggests that a reciprocal feedback regulatory
NuRD(MTA1) is implemented in mammary epithelium to dicta
epithelial cell plasticity in the mammary gland, whose dysfun
data provide a mechanistic link of the loss-of-function of GATA
underlying the opposing action ofMTA1 andMTA3 in breast ca
complexity of the hierarchical regulatory network of EMT and su
the potential prognostic indicators or/and therapeutic targets
822 Cancer Cell 27, 822–836, June 8, 2015 ª2015 Elsevier Inc.cancers (Usary et al., 2004), and GATA3 was reported to be
one of three genes mutated in >10% of all breast cancers (The
Cancer Genome Atlas Network, 2012). However, how lost
expression/loss-of-function of GATA3 contributes to the
dissemination and metastasis of breast cancer is still poorly
understood.
G9A/Eu-HMTase2/KMT1C is a histone lysine methyltransfer-
ase that biochemically catalyzes mono- and di-methylation of
H3K9 (H3K9me1 and H3K9me2) in euchromatin and is function-
ally linked to transcription repression (Collins et al., 2008; Feld-
man et al., 2006; Tachibana et al., 2002). Interestingly, although
gene ablation of G9a in mice results in embryonic lethality,
G9a/ embryonic stem cells do not show overt growth abnor-
malities in culture conditions, but exhibit severe differentiation
defects, suggesting a role for G9A in cell differentiation andloop between GATA3/G9A/NuRD(MTA3) and ZEB2/G9A/
te the epithelial cell fate and to govern the dynamics of the
ction contributes to the metastasis of breast cancer. Our
3 to breast cancer progression and a molecular mechanism
ncer progression. Our results add to the understanding of the
pport the pursuit of GATA3, ZEB2, G9A, andMTA1/MTA3 as
of breast cancer.
lineage commitment (Tachibana et al., 2002). Importantly, G9A
has also been implicated in the development and progres-
sion of a variety of human cancers including hepatocellular,
colon, prostate, lung, and bladder carcinomas (Shankar et al.,
2013).
MTA (metastasis tumor antigen) family proteins, MTA1, MTA2,
and MTA3, are the integral component of the Mi-2/nucleosome
remodeling and deacetylase (NuRD) complex that is primarily
implicated in transcription repression (Wang et al., 2009; Zhang
et al., 1998). It is believed that the members of MTA family do not
co-localize in the same NuRD complex and do not functionally
substitute for each other (Denslow and Wade, 2007; Fujita
et al., 2003; Yao and Yang, 2003). Intriguingly, although all
MTA1, MTA2, and MTA3 have been implicated in cancer pro-
gression and metastasis (Denslow and Wade, 2007; Kumar,
2003; Manavathi and Kumar, 2007), it was noted that MTA1
and MTA3 exhibit opposite patterns of expression during breast
cancer: similar to GATA3, MTA3 is highly expressed in epithelial
cells, and its expression is progressively lost during breast can-
cer progression, whereas MTA1 expression progressively in-
creases during the process (Zhang et al., 2006). Functionally,
MTA1 promotes breast tumor progression, whereas MTA3 has
an opposing role by inhibiting epithelial-to-mesenchymal transi-
tion (EMT) (Fujita et al., 2003). However, the molecular mecha-
nism underlying the opposite functionality of MTA1 and MTA3
in breast cancer development is still not understood.
EMT programs are coordinated by a set of pleiotropic
transcription factors including SNAIL, TWIST, and zinc-finger
E-box-binding (ZEB) transcription factors. The two vertebrate
ZEB transcription factors, ZEB1 and ZEB2, can either repress
or activate transcription (Peinado et al., 2007). It has been re-
ported that ZEB2 is expressed in breast cancer cells and its level
of expression is negatively correlated with that of the epithelial
marker E-cadherin (Lee et al., 2014). However, how ZEB2 coor-
dinates with other EMT regulators and contributes to breast can-
cer progression are largely unexplored.
In this study, we addressed the issue of how loss of function of
GATA3 contributes to the development of breast cancer. We
explored the molecular mechanism underlying the opposing ac-
tion of MTA1 and MTA3 and investigated the functional interplay
between GATA3 and ZEB2, two master regulators of EMT, in
breast cancer progression.
RESULTS
GATA3 Is Physically Associated with G9A and the
NuRD(MTA3) Complex
To understand how the loss of function of GATA3 contributes to
the breast cancer metastasis, we first employed affinity purifica-
tion and mass spectrometry to interrogate GATA3 interactome
in vivo. In these experiments, FLAG-tagged GATA3 (FLAG-
GATA3) was stably expressed in human breast adenocarcinoma
cell line MCF-7. Whole cell extracts were prepared and sub-
jected to affinity purification using an anti-FLAG affinity gel.
Mass spectrometric analysis indicates that GATA3 was co-puri-
fied with MTA3, HDAC1, HDAC2, RbAp46, RbAp48, all compo-
nents of the NuRD complex, as well as with G9A, a H3K9
methyltransferase (Figure 1A). The presence of G9A and the
NuRD subunits in the GATA3 interactome was confirmed bywestern blotting analysis of the column-bound proteins with
antibodies against the corresponding proteins (Figure 1A, right).
The detailed result of the mass spectrometric analysis is pro-
vided in Table S1.
To further support the in vivo interaction between GATA3,
G9A, and the NuRD complex, total proteins from MCF-7 cells
were extracted and co-immunoprecipitation experiments were
performed with antibodies detecting the endogenous proteins.
Immunoprecipitation (IP) with antibodies against GATA3 fol-
lowed by immunoblotting (IB) with antibodies against G9A,
Mi-2, LSD1, HDAC1, HDAC2, RbAp46/48, MBD3, MTA1,
MTA2, orMTA3 demonstrated that all the tested proteins, except
for MTA1 and MTA2, were efficiently co-immunoprecipitated
with GATA3 (Figure 1B). Reciprocally, IP with antibodies against
G9A or components of the NuRD(MTA1/2/3) complex followed
by IB with antibodies against GATA3 also showed that GATA3
was efficiently co-immunoprecipitated by G9A and all the com-
ponents of the NuRD complex except for MTA1 and MTA2 (Fig-
ure 1B, right). These results suggest that GATA3 is physically
associated with G9A andMTA3-, but notMTA1- orMTA2-, asso-
ciated NuRD complex in vivo. Corroborating with this, IP using
equal amounts of MCF-7 cellular extracts with antibodies
against MTA1 or MTA3, followed by immunoblotting with anti-
bodies against GATA3, G9A, MTA1, MTA2, MTA3, Mi-2,
HDAC1, or MBD3 indicate that while G9A was co-immunopre-
cipitated with both MTA1 and MTA3, GATA3 was only co-immu-
noprecipitated with MTA3 (Figure 1C).
To verify the presence of a GATA3/G9A/NuRD(MTA3) com-
plex in vivo, MCF-7 nuclear proteins were fractionated by
fast protein liquid chromatography (FPLC) with Superose 6
columns and a high salt extraction and size exclusion
approach. We found that the native GATA3 from MCF-7 cell
nuclear extracts was eluted with an apparent molecular mass
much greater than that of the monomeric protein; GATA3
immunoreactivity was detected in chromatographic fractions
from the Superose 6 column with a relative symmetric peak
centered between 669 and 2,000 kDa (Figure 1D). Signifi-
cantly, the elution pattern of GATA3 largely overlapped with
that of G9A and the NuRD complex proteins including Mi-2,
MTA proteins, HDAC2, and RbAp46/48. Furthermore, western
blotting of FLAG-GATA3 affinity eluate from FPLC after
Superose 6 gel filtration revealed that GATA3 was only co-
immunoprecipitated with MTA3 (Figure 1E). These observations
support the existence of the GATA3/G9A/NuRD(MTA3) com-
plex in vivo.
To substantiate the observation that GATA3 is specifically
associated with the MTA3-consitituted NuRD complex, affinity
purification and mass spectrometry were utilized again to
analyze G9A-, MTA1-, and MTA3-associated proteins in vivo.
Notably, G9A was co-purified with GATA3, Mi-2, LSD1,
HDAC1, HDAC2, RbAp46, RbAp48, MBD3, and all three MTA
family members, MTA1, MTA2, and MTA3 (Figure 1F). The pres-
ence of these proteins in the G9A-containing complex was
confirmed by western blotting analysis of the column-bound
proteins with antibodies against the corresponding proteins (Fig-
ure 1F, right). Interestingly, however, although G9A was co-puri-
fied with both MTA1 and MTA3, GATA3 was only found in the
MTA3-containing protein complex (Figure 1G). These results
were confirmed by co-IP experiments in MCF-7 cells andCancer Cell 27, 822–836, June 8, 2015 ª2015 Elsevier Inc. 823
Figure 1. GATA3 Interacts with G9A and the
MTA3-Associated NuRD Complex
(A) Cellular extracts from MCF-7 cells stably ex-
pressing FLAG (control) or FLAG-GATA3 were
immunopurified with anti-FLAG affinity columns
and eluted with FLAG peptide. The eluates were
resolved by SDS-PAGE and silver-stained. The
protein bands were retrieved and analyzed by
mass spectrometry. Column-bound proteins were
analyzed by western blotting using antibodies
against the indicated proteins.
(B) Whole cell lysates from MCF-7 cells were pre-
pared and co-IP was performed with antibodies
against the indicated proteins. Immunocomplexes
were then IB using antibodies against the indicated
proteins.
(C) Equal amounts of MCF-7 cellular extracts were
immunoprecipitated with antibodies against MTA1
or MTA3 followed by IB with antibodies against the
indicated proteins.
(D) Nuclear extracts of MCF-7 cells were fraction-
ated on Superose 6 size exclusion columns.
Chromatographic elution profiles and IB analysis
of the chromatographic fractions are shown. Equal
volume from each fraction was analyzed and the
elution positions of calibration proteins with known
molecular masses (kDa) are indicated.
(E) Silver staining and western blotting of
the GATA3-containing complex fractionated by
Superose 6 gel filtration.
(F and G) Immunopurification and mass spectro-
metric analysis of G9A-, MTA1-, or MTA3-con-
taining proteins in MCF-7 cells.
(H) Whole cell lysates from MCF-7 cells or MDA-
MB-231 cells were immunoprecipitated with
antibodies against the indicated proteins. Im-
munocomplexes were then IB using antibodies
against the indicated proteins.
See also Tables S1, S2, S3, and S4.MDA-MB-231 cells (Figure 1H). Altogether, the above experi-
ments indicate that GATA3 specifically interacts with G9A and
the MTA3-associated NuRD in vivo. The detailed result of
the mass spectrometric analysis is provided in Tables S2,
S3, and S4.824 Cancer Cell 27, 822–836, June 8, 2015 ª2015 Elsevier Inc.Molecular Interaction between
GATA3, G9A, and the NuRD(MTA3)
Complex
To further support the physical associa-
tion between GATA3, G9A, and the
NuRD(MTA3) complex and to gain in-
sights into the molecular details involved
in the interaction of these proteins, gluta-
thione S-transferase (GST) pull-down
experiments were then performed by in-
cubation of GST-fused GATA3 with
in vitro transcribed/translated individual
components of the NuRD complex
including G9A, LSD1, MTA1, MTA2,
MTA3, HDAC1, HDAC2, RbAp46,
RbAp48, and MBD3. We showed that
GATA3 interacts directly with G9A andMTA3, but not with the other components of the NuRD complex
tested (Figure 2A). Reciprocal GST pull-down experiments
with GST-fused G9A, LSD1, MTA1, MTA2, MTA3, HDAC1,
HDAC2, RbAp46, RbAp48, or MBD3 and in vitro transcribed/
translated GATA3 yielded similar results (Figure 2B). In addition,
Figure 2. Molecular Interaction between
GATA3, G9A, and the NuRD Complex
(A–H) GST pull-down assays with GST-fused
proteins and in vitro transcribed/translated pro-
teins as indicated.
(I) Schematic diagram depicting the molecular
interaction between GATA3, G9A, and MTA3 is
shown.GST pull-down assays with GST-fused N-terminal fragment
(1–222 amino acid [aa], GATA3-N), the zinc finger domain (222–
333 aa, GATA3-ZnF), or the C-terminal fragment (333–444 aa,
GATA3-C) of GATA3 and in vitro transcribed/translated G9A or
MTA3 indicated that the N-terminal region of GATA3 is respon-
sible for its interaction with MTA3 and the zinc finger region of
GATA3 is responsible for its interaction with G9A (Figure 2C).
Analogously, GST pull-down assays with GST-fused G9A and
in vitro transcribed/translated components of the NuRD com-
plexes revealed that G9A is able to interact with all three MTA
proteins, MTA1, MTA2, and MTA3 (Figure 2D), consistent with
the results from affinity purification and co-IP described above.
Reciprocal GST pull-down experiments with GST-fused NuRDCancer Cell 27, 822–components and in vitro transcribed/
translated G9A yielded similar results
(Figure 2E). Likewise, GST pull-down as-
says with GST-fused G9A N-terminal
fragment (1–266 aa, G9A-N), the ANK
repeat domain (266–744 aa, G9A-ANK),
or the SET domain (676–1211 aa, G9A-
SET) and in vitro transcribed/translated
GATA3 or MTA1/2/3 demonstrated that
the ANK repeat domain of G9A is
responsible for its interaction with
MTAs and GATA3 (Figure 2F). Moreover,
GST pull-down assays with GST-fused
N-terminal fragment (MTA-N), middle re-
gion (MTA-M), or C-terminal fragment
(MTA-C) of MTA1/2/3 and in vitro tran-
scribed/translated G9A or GATA3 sug-
gest that the Swi3-Ada2-N-CoR-TFIIIB
(SANT) domain of MTAs is responsible
for the interaction of MTA1/2/3 with G9A
and of MTA3 with GATA3 (Figures 2G
and 2H). Together, these results not only
provided further support of the specific
interaction between GATA3, G9A, and
the NuRD(MTA3) complex, but also
delineated the molecular detail involved
in the formation of the GATA3/G9A/
NuRD(MTA3) complex, as schematically
summarized (Figure 2I).
Identification of Genome-wide
Transcription Targets for the
GATA3/G9A/NuRD(MTA3) Complex
As mentioned earlier, GATA3 is a tran-
scription factor acting to either activate
or repress gene transcription. However,both G9A and the NuRD(MTA3) complex are mainly implicated
in gene transcription repression. The association of GATA3
with G9A and the NuRD(MTA3) complex suggest that the
GATA3-nucleated chromatin modifying complex GATA3/G9A/
NuRD(MTA3) constitutes a repression program functioning to
inhibit gene transcription. In order to explore the functional sig-
nificance of the physical association between GATA3, G9A,
and the NuRD(MTA3) complex, we analyzed the genome-wide
transcriptional targets of the GATA3/G9A/NuRD(MTA3) complex
by chromatin IP-based deep sequencing (ChIP-seq). In these
experiments, ChIP experiments were performed first in MCF-7
cells with antibodies against GATA3, G9A, or MTA3. Follow-
ing ChIP, GATA3-, G9A-, and MTA3-associated DNAs were836, June 8, 2015 ª2015 Elsevier Inc. 825
Figure 3. Genome-wide Transcription Target Analysis for the GATA3/G9A/NuRD(MTA3) Complex
(A) Genomic distribution of GATA3, G9A, and MTA3 determined by ChIP-seq analysis.
(B) The Venn diagram of overlapping promoters bound by GATA3, G9A, and MTA3 in MCF-7 cells (left). The clustering of the 206 overlapping target genes of
GATA3/G9A/MTA3 into functional groups is shown (right). The detailed results of the ChIP-seq experiments are provided in the Supplemental Experimental
Procedures.
(C) GATA3-, G9A-, and MTA3-bound motifs were analyzed using MEME suite.
(D) The binding of GATA3, G9A, and MTA3 on representative target genes, ZNF217 and BCAS3. The chromosome number and position of the peak bound by
each of the proteins are shown.
(E) ChIP-seq density heatmaps of G9A, MTA3, H3K9me1, and H3K14ac on GATA3 binding sites.
(F) Verification of the ChIP-seq results by qChIP analysis of the indicated genes in MCF-7 cells. Results are represented as fold change over control with
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a negative control. Error bars represent mean ± SD for three independent experiments (*p < 0.05,
**p < 0.01, and two-tailed unpaired t test).
See also Table S5.amplified using non-biased conditions, labeled, and then
sequenced. Using HiSeq2000 and with a p value cutoff of
105, we identified 9,934 GATA3-specific binding peaks,
14,480 G9A-specific binding sites, and 18,750 MTA3-specific
binding sequences (Figure 3A) (GEO accession number:
GSE67206). The data from GATA3, G9A, and MTA3 groups
were then analyzed for overlapping DNA sequences/gene pro-
moters, and these promoters were considered to be the targets
of the GATA3/G9A/NuRD(MTA3) complex. These experiments
identified a total of 206 different promoters targeted by GATA3,826 Cancer Cell 27, 822–836, June 8, 2015 ª2015 Elsevier Inc.G9A, and MTA3. The corresponding genes to these promoters
were then classified into various cellular signaling pathways us-
ingMolecule Annotation System softwarewith a p value cut off of
103. These signaling pathways include metabolic, P13K-Akt,
focal adhesion, cell cycle, cell adhesion, Wnt, p53, and TGF-b
pathways that are critically involved in cell growth, survival,
migration, and invasion (Figure 3B). Significantly, we found that
GATA3, G9A, and MTA3 had similar binding motifs (Figure 3C),
genomic distributions, and peak locations on the proximal pro-
moter of the target genes such as BCAS3 and ZNF217
(Figure 3D), supporting the notion that GATA3, G9A, and MTA3
physically interact and are functionally linked.
We also analyzed the genomic landscapes of theGATA3/G9A/
NuRD(MTA3) complex as well as the enzymatic activities associ-
ated with this complex by intercrossing GATA3/G9A/MTA3
ChIP-seq data with published ChIP-seq results for various his-
tone modifications in MCF-7 cells (Wu et al., 2013). Comparing
the characteristic enrichment of G9A, MTA3, H3K9me1, and
H3K14 acetylation (H3K14ac) at GATA3 binding sites versus
randomly selected genomic control regions revealed that G9A,
MTA3, and H3K9me1 were significantly enriched in regions sur-
rounding the GATA3 genomic binding sites, whereas H3K14ac
exhibited little difference between GATA3 binding sites and the
non-specific regions (Figure 3E). Detailed results of the ChIP-
seq experiments are provided in Table S5 and deposited in
GEO data sets.
Quantitative ChIP (qChIP) analysis in MCF-7 cells using spe-
cific antibodies against GATA3, G9A, MTA3, or Mi-2 on selected
genes including VAPB, STAG, NIF, MYC, MDM2, AIP1, ACTR6,
ZNF217, BCAS3, TGFB1, NCOA3, TWISTNB, MLL5, FOSL,
CDH2 (N-cadherin), FN1 (Fibronectin), and ZEB2 that represent
each of the classified pathways showed a strong enrichment
of GATA3, G9A, MTA3, and Mi-2 on the promoters of these
genes, validating the ChIP-seq results (Figure 3F). In addition,
qChIP analysis with specific antibodies against H3K9me1 and
H3K9me2, two catalytic products of G9A, showed that the target
promoters were indeed marked with H3K9me1 and H3K9me2
(Figure 3F), further supporting the occupancy of these promoters
by G9A.
The Formation of the GATA3/G9A/NuRD(MTA3)
Repression Complex on Transcriptional Targets
In order to support the notion that GATA3, G9A, and MTA3
occupy the target promoters in the context of the GATA3/G9A/
NuRD(MTA3) complex, MCF-7 cell clones with GATA3, G9A, or
MTA3 stably depleted were generated by lentivirus-delivered
short hairpin RNA (shRNA) (Figures 4A and S1). qChIP experi-
ments indicated that while depletion of either GATA3, G9A, or
MTA3 resulted in a marked reduction of the recruitment of the
corresponding proteins at the promoters of the target genes,
depletion of G9A or MTA3 resulted in only marginal or no effect
on the recruitment of GATA3 (Figure 4B). However, when
GATA3 was depleted, the recruitment of G9A and MTA3, as
well as Mi-2, to the target promoters was dramatically reduced
(Figure 4B), although the expression of G9A and MTA3 was not
affected by GATA3 knockdown (Figure 4A). Consistently, the
levels of H3K9me1 and H3K9me2 were markedly decreased
at all the tested target promoters upon knockdown of either
G9A or GATA3, while the level of pan-H3 acetylation (H3Ac)
was significantly increased when either MTA3 or GATA3 was
depleted (Figure 4C). Interestingly, although G9A and MTA3
had little effect on each other’s chromatin binding (Figure 4B),
their catalytic activities appeared to be interdependent (Fig-
ure 4C). These results point to a scenario in which the chromatin
modifying enzymes G9A and NuRD(MTA3) are recruited on
target gene promoters by GATA3, supporting the existence of
GATA3, G9A, and the NuRD(MTA3) in the same protein complex
on target gene promoters and the functional coordination be-
tween these chromatin modifiers.To further support the proposition that GATA3 nucleates G9A
and NuRD(MTA3) to form one protein complex at target pro-
moters, sequential ChIP or ChIP/Re-ChIP experiments were per-
formed on four representative target genes, ZEB2, BCAS3,
TGFB1, and N-cadherin. In these experiments, soluble chroma-
tins were first immunoprecipitated with antibodies against
GATA3, G9A, or MTA3. The immunoprecipitates were subse-
quently re-immunoprecipitated with appropriate antibodies.
The results showed that, in precipitates, the ZEB2, BCAS3,
TGFB1, and N-cadherin promoters that were immunoprecipi-
tatedwith antibodies against GATA3 could be re-immunoprecip-
itated with antibodies against G9A or MTA3 (Figure 4D). Similar
results were obtained when initial ChIP was done with antibodies
against G9A or MTA3 (Figure 4D). These results support the
argument that GATA3, G9A, and the NuRD(MTA3) complex
occupy the ZEB2, BCAS3, TGFB1, and N-cadherin promoters
as one protein complex. In agreement with this, depletion
of GATA3, G9A, or MTA3 in MCF-7 cells led to increased ex-
pression of ZEB2, BCAS3, TGFB1, and N-cadherin (Figure 4E,
left).
The GATA3/G9A/NuRD(MTA3) Complex Inhibits EMT
and the Invasive Potential of Breast Cancer Cells In Vitro
and Suppresses Breast Cancer Metastasis In Vivo
As stated above, our genome-wide analysis indicates that the
GATA3/G9A/NuRD(MTA3) targets several cellular signaling
pathways that are critically involved in cell migration and inva-
sion. In order to further support the physical interaction and to
explore the functional connection between GATA3, G9A, and
the NuRD(MTA3) complex, we next investigated the role of the
GATA3/G9A/NuRD(MTA3) complex in invasion and metastasis
of breast cancer. To this end, gain of function and loss of function
of GATA3, G9A, or MTA3 experiments were performed, and the
expression of epithelial/mesenchymal markers was analyzed
and the morphological alterations were examined in MCF-7
cells. We found that overexpression of either GATA3, G9A, or
MTA3 resulted in induction, at both mRNA and protein levels,
of epithelial protein markers including E-cadherin, a-catenin,
and g-catenin and reduction of mesenchymal markers including
N-cadherin, fibronectin, and vimentin, and co-overexpression of
G9A and MTA3 led to more pronounced changes in the expres-
sion of these markers (Figure 5A). Consistently, depletion of
GATA3, G9A, or MTA3 individually or in combination resulted
in the reduction of epithelial markers and induction of mesen-
chymal markers (Figures 5B and S2A). Moreover, experiments
with GATA3 depletion indicated that the induction or depression
of thesemarkers by overexpression of G9A andMTA3 is, at least
partially, dependent of GATA3 (Figure 5C). Morphologically,
while control cells maintained organized cell-cell adhesion and
cell polarity, GATA3-, G9A-, or MTA3-deficient cells exhibited
loss of cell-cell contacts; cells became scattered and their
cobble stone-like appearance was replaced by a spindle-like,
fibroblastic morphology, indicative of characteristic morpholog-
ical changes of EMT (Figure S2B). Consistently, immunofluores-
cent microscopic analysis showed a reduced or lost membrane
staining of epithelial markers E-cadherin and a-catenin in
GATA3-, G9A-, or MTA3-depleted MCF-7 cells, while the stain-
ing of the mesenchymal markers N-cadherin and fibronectin ex-
hibited a reverse trend (Figure S2B).Cancer Cell 27, 822–836, June 8, 2015 ª2015 Elsevier Inc. 827
Figure 4. The Formation of the GATA3/G9A/NuRD(MTA3) Complex on Transcription Targets
(A) MCF-7 cells were infected with lentivirus carrying control shRNA (shSCR) or shRNAs targeting GATA3, G9A, or MTA3. The knockdown efficiencies of GATA3,
G9A, and MTA3 were verified by real-time RT PCR and western blotting.
(B and C) MCF-7 cells were infected with lentiviruses carrying the indicated shRNAs. qChIP analysis of the selected promoters was performed using antibodies
against GATA3, G9A, MTA3, or Mi-2 (B) or against H3K9me1, H3K9me2, or H3Ac (C). H3 was detected as an internal control. Results are represented as fold
change over control with GAPDH as a negative control.
(D) ChIP and Re-ChIP experiments in MCF-7 cells with the indicated antibodies.
(E) Real-time RT PCR and western blotting analyses of the expression of ZEB2, BCAS3, TGFB1, and N-cadherin in MCF-7 cells infected with lentiviruses carrying
the indicated shRNAs. Error bars represent mean ± SD for three independent experiments (*p < 0.05, **p < 0.01, and two-tailed unpaired t test).
See also Figure S1.We then investigated the roles of GATA3, G9A, and MTA3 in
cellular behavior of breast cancer cells in vitro using transwell in-
vasion assays. As shown in Figure 5D, knockdown of GATA3,
G9A, or MTA3 led to an increase in the invasive potential of
MCF-7 cells, whereas overexpression of either GATA3, G9A, or
MTA3 resulted in a decrease in the invasive potential of MDA-
MB-231 cells. Significantly, in agreement with the functional
link between GATA3/G9A/MTA3 and ZEB2 described earlier,
the positive effect of GATA3/G9A/MTA3 knockdown on the inva-
sive potential of non-invasive MCF-7 cells could be offset by
transfection of cells with ZEB2 shRNA, while the inhibitory effect
on the invasive potential of the invasiveMDA-MB-231 cells asso-
ciated with GATA3, G9A, or MTA3 overexpression could be
offset by ectopic expression of ZEB2 (Figures 5D, S2C, and
S2D). In addition, the inhibitory effect of GATA3 overexpression828 Cancer Cell 27, 822–836, June 8, 2015 ª2015 Elsevier Inc.on invasiveness was probably achieved through a concerted ac-
tion by the G9A/MTA3/NuRD complex, as the effect of GATA3
overexpression was diminished when either G9A or MTA3 was
concomitantly knocked down in MDA-MB-231 cells (Figures 5D
and S2D). Taken together, these results support a critical role for
the GATA3/G9A/NuRD(MTA3) complex in the regulation of EMT
and invasion.
We then investigated the role of the GATA3/G9A/NuRD(MTA3)
complex in breast cancer metastasis in vivo. For this purpose,
MDA-MB-231 cells that were engineered to stably express firefly
luciferase (MDA-MB-231-Luc-D3H2LN, Xenogen) were co-in-
fected with lentiviruses carrying GATA3 and lentiviruses carrying
G9A shRNA or MTA3 shRNA. These cells were then ortho-
topically implanted onto nude mice or intravenously injected
into immunocompromised severe combined immunodeficiency
Figure 5. The GATA3/G9A/NuRD(MTA3)
Complex Inhibits the Invasive Potential of
Breast Cancer Cells In Vitro and Suppresses
Breast Cancer Metastasis In Vivo
(A–C) The expression of the indicated epithelial or
mesenchymalmarkers wasmeasured by real-time
RT PCR (left) or western blotting (right) in MCF-7
cells overexpressing GATA3, G9A, or/and MTA3
(A), MCF-7 cells with GATA3, G9A, or/and MTA3
depleted (B), or MCF-7 cells co-transfected with
shGATA3 and the expression plasmids for G9A or
MTA3 (C).
(D) Non-invasive MCF-7 cells and invasive MDA-
MB-231 cells were transfected with the indicated
specific shRNAs or/and expression constructs for
cell invasion assays. The invaded cells were
stained and counted. The images represent one
field under microscopy in each group. The effi-
ciency of protein knockdown or overexpression
was verified by western blotting.
(E and H) MDA-MB-231-Luc-D3H2LN cells in-
fected with lentiviruses carrying GATA3, GATA3,
and shRNA against G9A (GATA3+shG9A), or
GATA3 and shRNA against MTA3 (GATA3+
shMTA3) (E), shRNA against G9A or MTA3 (H)
were inoculated orthotopically into the abdominal
mammary fat pad of 6-week-old female nudemice
(n = 8). Primary tumors and metastases were
quantified using bioluminescence imaging after
7 weeks of initial implantation. Representative
in vivo bioluminescent images are shown (left), and
tumor specimens were examined by in vitro
bioluminescent measurement (middle).
(F and I) The above-described MDA-MB-231-Luc-
D3H2LN cells were injected intravenously through
the tail vein of 6-week-old female SCID mice
(n = 8). Lung metastasis was quantified using
bioluminescence imaging after 6 weeks. Repre-
sentative in vivo bioluminescent images are shown
(left). Lung cancer specimens were examined by
in vitro bioluminescent measurement and the
sections from normal (untreated) or GATA3+
shG9A-treated mice were stained with hematox-
ylin and eosin (H&E) (middle). Error bars indicate
mean ± SD (*p < 0.05, **p < 0.01, and two-tailed
paired t test).
(G and J) The protein expression in MDA-MB-231-
Luc-D3H2LN cells was confirmed by western
blotting.
See also Figure S2.(SCID) mice for themeasurements of spontaneousmetastasis or
seeding lung metastasis, respectively. Specifically, MDA-MB-
231-Luc-D3H2LN cells were either implanted onto the abdom-
inal mammary fat pad (n = 8) of 6-week-old female nude mice
or injected into the lateral tail vein (n = 8) of 6-week-old femaleCancer Cell 27, 822–SCID mice. The growth/dissemination of
tumorswasmonitoredweekly by biolumi-
nescence imaging with the IVIS imaging
system (Xenogen). Tumor metastasis
was measured by quantitative biolumi-
nescence imaging after 7 weeks for the
orthotopically implanted groups. For the
intravenous injection groups, the quanti-tative bioluminescence imaging was performed at 6 weeks after
injection. Ametastatic event was defined as any detectable lucif-
erase signal above background and away from the primary tu-
mor site. The results showed that, in the orthotopically implanted
groups, although GATA3 overexpression alone did not affect the836, June 8, 2015 ª2015 Elsevier Inc. 829
growth of the primary MDA-MB-231-Luc-D3H2LN tumors,
it resulted in a significant reduction in liver metastasis of the
tumors (Figure 5E). Remarkably, although no effect on the
growth of primary MDA-MB-231-Luc-D3H2LN tumors, deple-
tion of either G9A or MTA3 abrogated GATA3 overexpression-
associated suppression of the metastasis (Figure 5E). Similarly,
in the intravenous injection groups, GATA3 overexpression led
to a dramatic decrease in lung metastasis of the MDA-MB-
231-Luc-D3H2LN tumors and the suppressive effect of GATA3
overexpression on lung metastasis was, at least partially,
abolished when either G9A or MTA3 was knocked down
(Figure 5F). Themetastases to the lungswere verified by biolumi-
nescence imaging and histological staining (Figure 5F) and the
efficiency of overexpression or knockdownwas verified bywest-
ern blotting (Figure 5G). We also showed that knockdown of
either G9A orMTA3 promoted breast cancer metastasis (Figures
5H–5J). Collectively, these experiments indicate that GATA3
suppresses breast cancer metastasis in a G9A- and MTA3-
dependent manner, supporting a role for the GATA3/G9A/
NuRD(MTA3) complex in controlling the metastasis of breast
cancer in vivo.
Reciprocal Feedback Regulation by GATA3/G9A/
NuRD(MTA3) and ZEB2/G9A/NuRD(MTA1) in Controlling
Breast Cancer Progression
In order to gain further support of the role of the GATA3/G9A/
NuRD(MTA3) complex in breast cancer progression and to
extend our observations to a clinicopathologically relevant
setting, we collected 115 breast carcinoma samples from human
breast cancer patients and performed tissue microarrays by
immunohistochemical staining to examine the expression of
GATA3, G9A, and MTA3 in breast cancer samples (Figure 6A).
Strikingly, we found that the expression of GATA3, G9A, and
MTA3 is concurrently downregulated in breast cancer samples
and the levels of their expression are negatively correlated with
the histological grades of the tumors (Figure 6B). In addition,
consistent with our observation that ZEB2 is a downstream
target of the GATA3/G9A/NuRD(MTA3) complex, the expression
of ZEB2 was found to be upregulated in these breast cancer
samples and the level of its expression is positively correlated
with the histological grades of breast cancers (Figure 6B).
When the relative expression level of ZEB2 was plotted against
that of GATA3/G9A/MTA3 in 30 samples of grades I–II breast
carcinomas, statistically significant negative correlations were
observed (Figure 6C).
The concurrent downregulation of GATA3, G9A, and MTA3 in
breast carcinomas is intriguing. Nevertheless, this scenario fits
well to our working model that GATA3, G9A, and MTA3 are func-
tionally connected through formation of the GATA3/G9A/
NuRD(MTA3) complex. The question is how the expression of
GATA3, G9A, and MTA3 is all downregulated or concurrently
lost during breast cancer progression. Based on the reports
that ZEB2 is a transcription repressor and also a powerful regu-
lator of EMT (Gregory et al., 2008; Lamouille et al., 2014; Peinado
et al., 2007) and on our observations that ZEB2 is a downstream
target of the GATA3/G9A/NuRD(MTA3) complex, and is upregu-
lated in breast carcinomas, and that its expression is inversely
correlated with that of GATA3, G9A, or MTA3, it is possible
that elevated expression of ZEB2 is functionally linked to the830 Cancer Cell 27, 822–836, June 8, 2015 ª2015 Elsevier Inc.concurrent downregulation of GATA3, G9A, and MTA3. There
are two lines of evidence that support the hypothesis that
ZEB2 transcriptionally represses the expression of G9A and
MTA3, but not GATA3, in breast cancer cells: first, knockdown
of ZEB2 expression by its specific shRNA in MCF-7, MDA-MB-
231, T-47D, and MDA-MB-453 cells led to a derepression of
G9A and MTA3, but not GATA3 (Figure 6D); and second, ChIP
experiments detected that ZEB2, but not ZEB1, SNAI1 (Snail),
SNAI2 (Slug), TWIST1 (Twist) or TWIST2, indeed occupies the
promoters of G9A and MTA3 (Figure 6E).
In order to gain mechanistic insights into ZEB2-mediated
repression of G9A and MTA3, affinity purification and mass
spectrometry were utilized again to identify ZEB2 interactome
in MDA-MB-231 cells. The results indicated that ZEB2 is associ-
ated with a number of proteins including Mi-2, MTA1, MTA2,
HDAC1, HDAC2, RbAp46, RbAp48, and MBD3, all components
of the NuRD complexes, as well as G9A, in vivo (Figure 7A). The
presence of these proteins in ZEB2-associated complexes was
confirmed by western blotting analysis of the eluate with specific
antibodies against these proteins (Figure 7A, right). The detailed
result of themass spectrometric analysis is provided in Table S6.
FPLC assays revealed that ZEB2 immunoreactivity was de-
tected in MDA-MB-231 cell nuclear extracts in chromatographic
fractions from the Superose 6 column with a relative symmetric
peak centered between 669 and 2,000 kDa and the elution
pattern of ZEB2 largely overlapped with that of G9A and of the
NuRD complex proteins including MTA proteins, RbAp46/48,
and MBD3 (Figure 7B). Furthermore, western blotting of FLAG-
ZEB2 affinity eluate from FPLC after Superose 6 gel filtration re-
vealed that ZEB2 was only co-immunoprecipitated with MTA1/2
(Figure 7C). These observations support the existence of the
ZEB2/G9A/NuRD(MTA1/2) complex in vivo. Furthermore, IP
with anti-ZEB2 followed by IB with antibodies against G9A,
Mi-2, MTA1, MTA2, HDAC1, HDAC2, RbAp46/48, or MBD3 indi-
cated that all these proteins were efficiently co-immunoprecipi-
tated with ZEB2 (Figure 7D). Reciprocal co-IP with antibodies
against G9A, Mi-2, MTA1, MTA2, HDAC1, HDAC2, RbAp46/48,
or MBD3 followed by IB with anti-ZEB2 yielded similar results
(Figure 7D). Notably, both affinity purification and co-IP detected
no physical association between ZEB2 and MTA3. In addition,
GST pull-down with GST-fused LSD1, G9A, MTA1, MTA2,
MTA3, HDAC1, HDAC2, RbAp46, RbAp48, or MBD3 and
in vitro transcribed/translated ZEB2 revealed that ZEB2 interacts
with G9A aswell as withMTA1 andMTA2, but not withMTA3 and
other components of the NuRD complex tested (Figure 7E).
These experiments indicate that ZEB2 is physically associated
with G9A/NuRD(MTA1/2) through directly binding to G9A and
MTA1/MTA2.
To further delineate the molecular mechanism underlying
ZEB2-mediated transcription repression of G9A and MTA3,
MTA1 or MTA2 was overexpressed in MCF-7 cells or depleted
in MDA-MB-231 cells and the expression of G9A and MTA3
was measured by western blotting. The results of the experi-
ments indicated that overexpression of MTA1, but not MTA2,
was associated with a reduction of G9A and MTA3 in MCF-7
cells (Figure 7F). Likewise, knockdown of the expression of
MTA1, but not MTA2, resulted in an elevated expression of
G9A and MTA3 in MDA-MB-231 cells (Figure 7F). These exper-
iments suggest that ZEB2 represses the expression of G9A and
Figure 6. Reciprocal Feedback Regulation by GATA3/G9A/NuRD(MTA3) and ZEB2 G9A/NuRD(MTA1) in Controlling Breast Cancer
Metastasis
(A) Immunohistochemical staining of GATA3, G9A, MTA3, and ZEB2 in normal breast tissues and breast carcinomas (histological grades I, II, and III).
(B) The positively stained nuclei (%) in grouped samples were analyzed by two-tailed unpaired t test (*p < 0.05, **p < 0.01, and ***p < 0.001).
(C) The expression of GATA3, G9A, MTA3, or ZEB2 mRNAs was analyzed by real-time RT PCR in 30 paired breast carcinoma samples of grades I–II. The relative
level of ZEB2 was plotted against that of GATA3, G9A, or MTA3 with GAPDH as the reference.
(D)MCF-7,MDA-MB-231, T-47D, andMDA-MB-453 cells were treated with control shRNA or ZEB2 shRNA, and the expression of themRNA of GATA3, G9A, and
MTA3 was measured by real-time RT PCR.
(E) qChIP assays were performed using the indicated antibodies in MDA-MB-231 cells. Error bars represent mean ± SD for three independent experiments.MTA3 through formation of a ZEB2/G9A/NuRD(MTA1) com-
plex. To test this hypothesis, ChIP and Re-ChIP assays were
then performed on the promoters of G9A and MTA3. The re-
sults showed that ZEB2, G9A, MTA1, as well as Mi-2, occupy
the promoters of G9A and MTA3 in one protein complex (Fig-
ure 7G). In vitro transwell invasion assays indicated that
overexpression of ZEB2 in non-invasive MCF-7 cells was asso-
ciated with an increased invasiveness of the cells, an effect that
could be offset by simultaneous knockdown of MTA1 or over-
expression of either G9A or MTA3, whereas knockdown of
ZEB2 in invasive MDA-MB-231 cells resulted in a decreased
invasiveness of the cells, an effect that could be mimicked by
knockdown of either G9A or MTA3 (Figures 7H and S3). Collec-tively, these results support the argument that ZEB2 represses
the expression of G9A and MTA3 through recruitment of G9A
and the NuRD(MTA1) complex. Additionally, based on their
low expression in corresponding cell lines (Figure 7I), ZEB2 or
GATA3 was overexpressed in MCF-7 or MDA-MB-231 cells,
respectively. Equal amounts of cellular extracts were immuno-
precipitated with antibodies against ZEB2 or GATA3 followed
by IB with antibodies against Mi-2, HDAC1, MBD3, G9A,
MTA1, or MTA3 (Figure 7I). These experiments showed that
ZEB2 and GATA3 competitively interacted with G9A and
NuRD proteins except for MTA molecules. If our interpretation
of these results is correct, it means that a reciprocal feedback
regulatory loop exists between GATA3- and ZEB2-nucleatedCancer Cell 27, 822–836, June 8, 2015 ª2015 Elsevier Inc. 831
Figure 7. Transcription Repression of G9A
and MTA3 by the ZEB2/G9A/NuRD(MTA1)
Complex
(A) Immunopurification and mass spectrometric
analysis of ZEB2-associated proteins in MDA-MB-
231 cells. Column-bound proteins were detected
by western blotting using antibodies against the
indicated proteins (right). (B) Co-fractionation of
ZEB2 complex in MDA-MB-231 cells by FPLC.
(C) Silver staining and western blotting of ZEB2-
containing complex fractionated by Superose 6 gel
filtration.
(D) Co-IP assays in MDA-MB-231 cells.
(E) GST pull-down assays with the indicated
GST-fused proteins and in vitro transcribed/
translated ZEB2.
(F) MTA1 or MTA2 was overexpressed in MCF-7
cells or knocked down in MDA-MB-231 cells, the
expression of G9A and MTA3 in these cells was
detected by western blotting.
(G) ChIP and Re-ChIP experiments in MCF-7 cells
with the indicated antibodies.
(H) Non-invasive MCF-7 cells and invasive MDA-
MB-231 cells were transfected with the indicated
shRNAs or/and expression constructs for cell in-
vasion assays. Error bars indicate mean ± SD for a
representative experiment performed in triplicate
(*p < 0.05, **p < 0.01, and two-tailed unpaired
t test).
(I) ZEB2 was overexpressed in MCF-7 and GATA3
was overexpressed in MDA-MB-231 cells. Equal
amounts of MCF-7 or MDA-MB-231 cellular ex-
tracts were co-immunoprecipitated with anti-
bodies against ZEB2 or GATA3, followed by IBwith
the indicated antibodies.
(J) The proposed reciprocal feedback regula-
tory loop between GATA3/G9A/NuRD(MTA3) and
ZEB2/G9A/NuRD(MTA1).
See also Figure S3 and Table S6.repression programs in controlling the EMT and metastasis of
breast cancer (Figure 7J).
Finally, to further extend our observations to a clinicopatholog-
ically relevant context, we analyzed the expression of GATA3
and its correlation with clinical behaviors of breast cancer
patients. Kaplan-Meier survival analysis of GATA3/G9A with
another online tool (http://kmplot.com/analysis/) showed that
both higher GATA3 expression (p = 0.0065) and higher G9A832 Cancer Cell 27, 822–836, June 8, 2015 ª2015 Elsevier Inc.expression (p = 0.047) were associated
with a better overall survival of breast
cancer patients (n = 1,005), when the
influence of systemic treatment, endo-
crine therapy, and chemotherapy was
excluded (Figures 8A and S4). In addition,
although similar clinical data for MTA3 is
not available, Kaplan-Meier survival anal-
ysis of the published data sets (Ivshina
et al., 2006) demonstrated that higher
ZEB2 expression is associated with a
worse overall survival of the patients (p =
0.04681), and further stratification of pa-
tient groups based on the inverse expres-sion of GATA3/ZEB2 improved the predictive capability of ZEB2
(p = 0.012739) (Figure 8B), supporting ZEB2 being another signif-
icant predictor of survival. Moreover, analysis of three published
clinical data sets (GSE1456, GSE2034, and GSE4922) revealed
statistically significant negative correlations of expression be-
tween G9A and ZEB2 (Figure 8C), supporting our overall argu-
ment, although G9A was reported to repress E-cadherin and
promote breast cancer metastasis (Dong et al., 2012).
Figure 8. Clinicopothological Significance of GATA3/G9A/ZEB2 in Breast Cancer
(A) Kaplan-Meier survival analysis for the relationship between survival time and GATA3/G9A signature in breast cancer using the online tool (http://kmplot.com/
analysis/).
(B) Kaplan-Meier survival analysis of the published data sets (Ivhsina; GSE4922) for the relationship between survival time and ZEB2/GATA3 signature in breast
cancer.
(C) Analysis of public data sets (GSE1456, GSE2034, and GSE4922) for the expression of ZEB2, GATA3, and G9A. The relative level of ZEB2 was plotted against
that of G9A.
See also Figure S4.DISCUSSION
We report in this study that in breast cancer cells, GATA3 acts as
a transcriptional repressor that recruits chromatin remodeling
G9A/NuRD(MTA3) complex to inhibit the expression of a set of
genes including ZEB2, TGFB1, MDM2, ZNF217, and BCAS3
that are known to be critically involved in EMT, a hallmark of can-
cer metastasis (Hanahan and Weinberg, 2011). Interestingly, we
showed that the GATA3/G9A/NuRD(MTA3) complex also targets
the repression of a group of genes including N-cadherin and
Fibronecitin that represent the molecular markers of EMT.
Apparently, through a physical interaction, transcriptional regu-
lators GATA3, G9A, and the NuRD(MTA3) act in a concertedmanner and cooperated fashion to formulate a transcription
repression program to regulate the mammary epithelial plasticity
by controlling the hierarchical molecular network of EMT.
G9a/ embryonic stem cells show severe differentiation de-
fects (Tachibana et al., 2002), and, remarkably, mutant mice
with catalytically inactive G9A also have an embryonic lethal
phenotype similar to that of G9A knockout mice (Dodge et al.,
2004), suggesting that G9A-mediated H3K9 methylation is
important for its biological function. G9A catalyzes mono- and
di-methylation of H3K9 in euchromatin (Collins et al., 2008; Feld-
man et al., 2006; Shinkai and Tachibana, 2011; Tachibana et al.,
2002), prominent histone modifications that demarcate tran-
scription repression (Martin and Zhang, 2005). Our observationCancer Cell 27, 822–836, June 8, 2015 ª2015 Elsevier Inc. 833
that G9A is recruited to chromatin by GATA3 and represses gene
expression is consistent with these notions. In addition, we
showed that G9A directly interacts with all three members of
the MTA family and constitutes a facultative component of the
NuRD complex. It is believed that the NuRD complex contains
several subunits whose pattern of expression is heterogeneous
in various cell and tissue types, and it is proposed that subunit
heterogeneity confers these complexes with additional regula-
tory capacity and with unique functional properties (Bowen
et al., 2004; Denslow and Wade, 2007). In this regard, it is inter-
esting to note that previously we reported that the H3K4 deme-
thylases LSD1 (Wang et al., 2009) and JARID1B (Li et al., 2011)
are associated with the NuRD complex, expanding the enzy-
matic repertoire of the NuRD complex to include, in addition to
the ATPase and deacetylase, demethylase activity. Yet, our cur-
rent identification of the physical association and functional link
between G9A and the NuRD complex activity extends the enzy-
matic arsenal of the NuRD complex to include a histone methyl-
transferase. It is possible that G9A and LSD1 act in a coordinated
fashion in the context of the NuRD complex to simultaneously or
sequentiallymethylateH3K9 anddemethylate H3K4, two histone
modifications that are well linked to transcription repression. In
any event, it appears that Mi-2, MTAs, and HDAC1/2 represent
the compulsory components of the NuRD complex and consti-
tute the command center or headquarters of the NuRD complex,
which, through enlisting additional transcriptional co-regulators,
largely catalytic enzymes, to fulfill different missions.
We showed that NuRD/(MTA3) is recruited by GATA3 and
NuRD(MTA1) is recruited by ZEB2. Since GATA3 controls the
epithelial traits and the ZEB2 dictates the mesenchymal features
in mammary epithelium, our current study not only provides a
molecular basis for the opposing action of MTA3 and MTA1 in
breast cancer progression, but also adds to the understanding
of the molecular interplays involved in the sophisticated regula-
tory network of EMT, although it remains to be delineated the in-
terplays among different regulatory pathways including GATA3,
ZEB2, Snail, Twist, and others that control EMT processes.
Moreover, it is possible that differential usage of MTA species
is tissue specific. For example, GATA3 has been previously re-
ported to physically interact with MTA2 in Th2 cells (Hwang
et al., 2010).
We showed that the GATA3/G9A/NuRD(MTA3) complex is a
potent suppressor of breast cancer metastasis through targeting
the promoters of an array of genes that represent several impor-
tant cellular signaling pathways regulating cell migration and in-
vasion. A number of the genes, including ZEB2, ZFXH1B, SIP1,
MDM2, ZNF217, and BCAS3 have been implicated in the devel-
opment and progression of a variety of humanmalignancies, and
suppression of breast cancer invasion andmetastasis by GATA3
has also been reported by others (Chou et al., 2013; Yan et al.,
2010). It is probably too early to call the GATA3/G9A/
NuRD(MTA3) complex a master suppressor of EMT and metas-
tasis. Nevertheless, our observation that the GATA3/G9A/
NuRD(MTA3) complex transcriptionally represses all the above
genes positions the GATA3/G9A/NuRD(MTA3) complex up-
stream of these genes and places GATA3/G9A/MTA3 at the
node of the hierarchical regulatory network of EMT, providing
mechanistic insights into the functional similarity and interplays
of above-described genes in the development and progression834 Cancer Cell 27, 822–836, June 8, 2015 ª2015 Elsevier Inc.of breast cancer. Of note, we showed that overexpression of
GATA3 did not affect the growth of primary tumors, whereas
studies by others reported that this condition did affect the
growth of primary tumors (Chou et al., 2013; Yan et al., 2010).
The reason behind this discrepancy needs further investigation.
Yet, ZEB2 is at another epicenter and represents another node
of the hierarchical regulatory network of EMT. However, contrary
to GATA3, ZEB2 is a powerful promoter of EMT. Acting as a tran-
scription repressor and through downregulation of E-cadherin
and microRNA miR-200 family and upregulation of mesen-
chymal markers (Gregory et al., 2008; Peinado et al., 2007),
ZEB2 positively influences cellular signaling pathways including
TGFb and Wnt pathway to promotes EMT and metastasis. Thus,
the transcription repression of ZEB2 by the GATA3/G9A/
NuRD(MTA3) complex is of particular significance. In effect,
GATA3, through the aid of G9A/NuRD(MTA3), inhibits the
expression of the mesenchymal promoter ZEB2 and maintains
the luminal cell fate in mammary epithelium. Upon loss of func-
tion of GATA3 due to lost expression or mutations, which occurs
frequently in breast cancer (Kouros-Mehr et al., 2008; Mehra
et al., 2005; The Cancer Genome Atlas Network, 2012; Usary
et al., 2004; Yoon et al., 2010), the expression of ZEB2 is dere-
pressed, and elevated ZEB2 promotes EMT and metastasis.
Although this is a logic scenario to explain how loss of function
of GATA3 contributes to the progression of breast cancer, it is
apparently not the whole story. We found that, surprisingly, the
expression of GATA3, G9A, and MTA3 is concurrently downre-
gulated in advanced breast carcinomas and we demonstrated
that ZEB2 is the culprit. We showed that ZEB2, through recruit-
ment of G9A and the MTA1-constituted NuRD complex,
represses the expression of G9A andMTA3. Apparently, a recip-
rocal feedback regulatory loop exists in which loss of function of
GATA3 in breast cancer leads to an elevated expression of
ZEB2, which, in turn, further downregulates G9A and MTA3 to
maintain its high level of expression, promotes EMT, and, even-
tually, leads to the metastasis of breast cancer. In this loop,
although G9A acting to repress itself initially appears to be enig-
matic, it nonetheless might be an integral component of the
mechanism and represent a rate-limiting factor in this system.
In summary, our results suggest that a reciprocal feedback
regulatory loop between GATA3/G9A/NuRD(MTA3) and ZEB2/
G9A/NuRD(MTA1) is implemented in mammary epithelium to
dictate the epithelial cell fate and to govern the dynamics of
the epithelial cell plasticity in the mammary gland, whose
dysfunction affects the fate of mammary epithelial cells and con-
tributes to the metastasis of breast cancer. Our data provide
a mechanistic link of the loss of function of GATA3 to breast can-
cer progression and a molecular mechanism underlying the
opposing action ofMTA1 andMTA3 in the development and pro-
gression of breast cancer. Our results add to the understanding
of the complexity of the hierarchical regulatory network of EMT
and support the pursuit of GATA3, ZEB2, G9A, and MTA1/
MTA3 as the potential prognostic indicators or/and therapeutic
targets of breast cancer.EXPERIMENTAL PROCEDURES
For a detailed description of all methods, see the Supplemental Experimental
Procedures.
In Vivo Metastasis
MDA-MB-231 cells that had been transfected to stably express firefly lucif-
erase (Xenogen) were infected with lentiviruses carrying empty vector,
GATA3 expression construct, control shRNA, shG9A, or shMTA3. These cells
were inoculated into the left abdominal mammary fat pad (34 3 106 cells) of
6-week-old female nude mice or injected into the lateral tail vein (13 3 106
cells) of 6-week-old female SCID mice. For bioluminescence imaging, mice
were injected with 200 mg/g of D-luciferin in PBS abdominally. At 15 min after
injection, mice were anesthetized and bioluminescence was imaged with a
charge-coupled device camera (IVIS; Xenogen). Bioluminescence images
were obtained with a 15 cm field of view, binning (resolution) factor of eight,
1/f stop, open filter, and an imaging time of 30 s to 2 min. Bioluminescence
from relative optical intensity was defined manually. Photon flux was normal-
ized to background, which was defined from a relative optical intensity
drawn over a mouse not given an injection of luciferin. Animal handling and
procedures were approved by the Tianjin Medical University Institutional
Animal Care.
Tissue Specimens
Normal mammary tissues, specimen with pathological grades I, II, and
III breast cancers, were procured from surgical specimens from patients
with breast cancer for which complete information on clinical tumor
size and metastatic status was available. All human tissue was collected
using protocols approved by the Ethics Committee of the Peking
University Health Science Center and informed consent was obtained from
all patients.
Statistical Analysis
Results were reported as mean ± SD unless otherwise noted. SPSS V.17.0
was used for statistical analysis. Comparisons between cancer and adjacent
normal tissue were performed using paired samples t test based on a bi-
directional hypothesis for continuous variables. Breast tumor data sets
were downloaded from http://www.ncbi.nlm.nih.gov/geo (Ivhsina; GSE4922,
Wang; GSE2034, Ivshina; GSE4922). The TCGA data were from http://
bioinformatics.mdanderson.org/main/TCPA:Overview. Data for Kaplan-
Meier survival analysis were from http://kmplot.com/analysis/index.php?
p=service&cancer=breast.
ACCESSION NUMBER
ChIP-seq data are deposited at the Gene Expression Omnibus database
(http://www.ncbi.nlm.nih.gov/geo/) with an accession number GSE67206.
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